- Concert Pharma press release ( NASDAQ: CNCE ): Q2 GAAP EPS of -$0.59 beats by $0.26 .
- Revenue of $0.02M (-99.9% Y/Y) misses by $0.06M .
For further details see:
Concert Pharma GAAP EPS of -$0.59 beats by $0.26, revenue of $0.02M misses by $0.06MFor further details see:
Concert Pharma GAAP EPS of -$0.59 beats by $0.26, revenue of $0.02M misses by $0.06MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Concert Pharmaceuticals Inc. Company Name:
CNCE Stock Symbol:
Market:
Concert Pharmaceuticals Inc. Website:
Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibit...
NEW YORK, NY / ACCESSWIRE / January 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Concert Pharmaceuticals, Inc. (NASDAQ...
If all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Mark...